BR112023002085A2 - Métodos para tratar hipercolesterolemia refratária envolvendo inibidor de angptl3 - Google Patents
Métodos para tratar hipercolesterolemia refratária envolvendo inibidor de angptl3Info
- Publication number
- BR112023002085A2 BR112023002085A2 BR112023002085A BR112023002085A BR112023002085A2 BR 112023002085 A2 BR112023002085 A2 BR 112023002085A2 BR 112023002085 A BR112023002085 A BR 112023002085A BR 112023002085 A BR112023002085 A BR 112023002085A BR 112023002085 A2 BR112023002085 A2 BR 112023002085A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- hypercholesterolemia
- involving
- angptl3
- statin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062990P | 2020-08-07 | 2020-08-07 | |
| US202163135946P | 2021-01-11 | 2021-01-11 | |
| PCT/US2021/045008 WO2022032137A1 (en) | 2020-08-07 | 2021-08-06 | Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002085A2 true BR112023002085A2 (pt) | 2023-02-28 |
Family
ID=77543654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002085A BR112023002085A2 (pt) | 2020-08-07 | 2021-08-06 | Métodos para tratar hipercolesterolemia refratária envolvendo inibidor de angptl3 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220072127A1 (https=) |
| EP (1) | EP4192446A1 (https=) |
| JP (1) | JP2023538522A (https=) |
| KR (1) | KR20230050379A (https=) |
| CN (1) | CN116096365A (https=) |
| AU (1) | AU2021320417A1 (https=) |
| BR (1) | BR112023002085A2 (https=) |
| CA (1) | CA3188213A1 (https=) |
| IL (1) | IL300429A (https=) |
| MX (1) | MX2023001481A (https=) |
| WO (1) | WO2022032137A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7541810B2 (ja) | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| KR20240167914A (ko) * | 2022-04-04 | 2024-11-28 | 이노자임 파마, 인코포레이티드 | Enpp1 결핍증 및 abcc6 결핍증의 치료 |
| WO2025185644A1 (zh) * | 2024-03-05 | 2025-09-12 | 江苏恒瑞医药股份有限公司 | 抗angptl3抗体治疗高血脂症的用途及方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| RU2723018C2 (ru) * | 2014-07-16 | 2020-06-08 | Санофи Байотекнолоджи | Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию |
| PL3169353T3 (pl) * | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
| JP7541810B2 (ja) * | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| KR20180132843A (ko) * | 2016-04-08 | 2018-12-12 | 리제너론 파아마슈티컬스, 인크. | Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법 |
| IL293308B2 (en) * | 2016-04-28 | 2024-12-01 | Regeneron Pharma | Methods for treating patients with familial hypercholesterolemia |
-
2021
- 2021-08-06 AU AU2021320417A patent/AU2021320417A1/en not_active Abandoned
- 2021-08-06 CA CA3188213A patent/CA3188213A1/en active Pending
- 2021-08-06 MX MX2023001481A patent/MX2023001481A/es unknown
- 2021-08-06 JP JP2023507911A patent/JP2023538522A/ja not_active Abandoned
- 2021-08-06 IL IL300429A patent/IL300429A/en unknown
- 2021-08-06 US US17/396,399 patent/US20220072127A1/en not_active Abandoned
- 2021-08-06 WO PCT/US2021/045008 patent/WO2022032137A1/en not_active Ceased
- 2021-08-06 EP EP21762903.9A patent/EP4192446A1/en not_active Withdrawn
- 2021-08-06 BR BR112023002085A patent/BR112023002085A2/pt unknown
- 2021-08-06 KR KR1020237007956A patent/KR20230050379A/ko active Pending
- 2021-08-06 CN CN202180058786.0A patent/CN116096365A/zh not_active Withdrawn
-
2023
- 2023-12-12 US US18/537,578 patent/US20240197870A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023001481A (es) | 2023-03-08 |
| US20240197870A1 (en) | 2024-06-20 |
| WO2022032137A1 (en) | 2022-02-10 |
| JP2023538522A (ja) | 2023-09-08 |
| AU2021320417A1 (en) | 2023-03-30 |
| KR20230050379A (ko) | 2023-04-14 |
| CN116096365A (zh) | 2023-05-09 |
| EP4192446A1 (en) | 2023-06-14 |
| IL300429A (en) | 2023-04-01 |
| US20220072127A1 (en) | 2022-03-10 |
| CA3188213A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023002085A2 (pt) | Métodos para tratar hipercolesterolemia refratária envolvendo inibidor de angptl3 | |
| AU2017258105A1 (en) | Methods for treating patients with familial hypercholesterolemia | |
| EA201691847A1 (ru) | Способы снижения сердечно-сосудистого риска | |
| MX386832B (es) | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. | |
| BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
| BR112018069732A2 (pt) | métodos para prevenir, tratar, reverter e/ou retardar angiogênese em um sujeito mamífero, para tratar um sujeito que sofre de uma doença ou condição angiogênica ocular e para inibir angiogênese do tumor | |
| BR112022024662A2 (pt) | Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2 | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| BR112022018157A2 (pt) | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer | |
| BRPI0211953B8 (pt) | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro | |
| BR112022026999A2 (pt) | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas | |
| EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
| BR112021017303A2 (pt) | Conjugado de anticorpo ou um sal ou solvato farmaceuticamente aceitável deste, anticorpo que se liga com especificidade ao dlk1 ou um fragmento de ligação ao antígeno deste, composição farmacêutica para prevenção ou tratamento de doença proliferativa, câncer ou angiogênica, métodos para prevenção e para tratamento de doença proliferativa, câncer ou angiogênica, e, uso do conjugado | |
| MX2018002000A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| BR112022016991A2 (pt) | Métodos para tratar um indivíduo humano que sofre de síndrome do desconforto respiratório agudo induzida por coronavírus ou pneumonia, para tratar, prevenir ou reduzir a gravidade ou coagulação ou trombose em um indivíduo humano infectado com vírus coronavírus da síndrome respiratória aguda grave 2 e para tratar, melhorar, prevenir ou reduzir o risco de desenvolver uma ou mais sequelas de longo prazo relacionadas ao coronavírus | |
| BR112022001395A2 (pt) | Métodos para administrar anticorpos anti-siglec-8 e corticosteroides | |
| BR112022015800A2 (pt) | Tratamento de colangite biliar primária com elafibranor | |
| BR112022003884A2 (pt) | Tratamento de doença ou distúrbio hepático compreendendo antagonistas do receptor de actrii | |
| BR112023021177A2 (pt) | Anticorpo, composição farmacêutica, uso do anticorpo, método para prevenir e/ou tratar um tumor, kit, formulação unitária, método para prevenir ou tratar um câncer ou tumor e unidade de dose única | |
| BR112023023453A2 (pt) | Anticorpo anti-tigit ou um fragmento de ligação ao antígeno deste e composições farmacêuticas compreendendo o referido anticorpo ou fragmento de ligação ao antígeno | |
| BR112019011350A2 (pt) | terapia de combinação | |
| BR112023015422A2 (pt) | Anticorpo anti-c1s | |
| BR112022020882A2 (pt) | Tratamento da hidradenite supurativa | |
| BR112021023748A2 (pt) | Terapia de combinação | |
| BR112021016913A2 (pt) | Método para tratar doenças relacionadas a tnfa |